RxSight Inc. (RXST)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Investing In The Future Of Cataract Surgery: The RxSight Advantage
RxSight, Inc. is transforming cataract surgery with the Light Adjustable Lens system, offering postoperative customization for superior vision outcomes. The global cataract devices market is rapidly expanding, with RxSight well-positioned to capitalize on the growing demand for premium IOLs. Impressive financial performance in Q2 2024, with significant revenue growth, gross profit margin improvement, and raised full-year revenue guidance.
Does RxSight (RXST) Have the Potential to Rally 27.64% as Wall Street Analysts Expect?
The mean of analysts' price targets for RxSight (RXST) points to a 27.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
RxSight, Inc. (RXST) Q2 2024 Earnings Call Transcript
RxSight, Inc. (NASDAQ:RXST ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants Ron Kurtz - President, Chief Executive Officer Shelley Thunen - Assistant Secretary, Chief Financial Officer Oliver Moravcevic - Vice President, Investor Relations Conference Call Participants Ryan Zimmerman - BTIG Robbie Marcus - J.P. Morgan Steven Lichtman - Oppenheimer & Co. Inc. David Saxon - Needham & Company Craig Bijou - Bank of America Larry Biegelsen - Wells Fargo Tom Stephan - Stifel Operator Good day and thank you for standing by.
RxSight, Inc. (RXST) Reports Break-Even Earnings for Q2
RxSight, Inc. (RXST) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.40 per share a year ago.
The 3 Best Med Tech Stocks to Buy Now
According to the Advanced Medical Technology Association, med tech is defined as “companies that develop, manufacture, and distribute the technologies, devices, equipment, diagnostic tests, and health information systems.” The organization reports that these firms favorably change health care with “earlier disease detection, less-invasive procedures, and more effective treatments.
Down -26.04% in 4 Weeks, Here's Why RxSight (RXST) Looks Ripe for a Turnaround
RxSight (RXST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
RxSight (RXST) Loses -16.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for RxSight (RXST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
What Makes RxSight, Inc. (RXST) a Strong Momentum Stock: Buy Now?
Does RxSight, Inc. (RXST) have what it takes to be a top stock pick for momentum investors? Let's find out.
